Trial Profile
Phase II study of OK-432 intrapleural administration followed by systemic carboplatin, pemetrexed and bevasizumab for non-squamous non-small cell lung cancer with pleuritis carcinomatosa
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Picibanil (Primary) ; Bevacizumab; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 May 2016 New trial record